Back
New Oriental Education & Technology Group 10K Form
Buy
68
EDU
New Oriental Education & Technology Group
Last Price:
38.60
Seasonality Move:
9.26%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive EDU News And Ratings
See the #1 stock for the next 7 days that we like better than EDU
EDU Financial Statistics
Sales & Book Value
| Annual Sales: | $3.11B |
|---|---|
| Cash Flow: | $173.67M |
| Price / Cash Flow: | 42.79 |
| Annual Sales: | $21.23 |
| Price / Book: | 1.82 |
Profitability
| EPS (TTM): | -1.39570 |
|---|---|
| Net Income (TTM): | $-245.01M |
| Gross Margin: | $1.35B |
| Return on Equity: | -6.4% |
| Return on Assets: | -3.79% |
New Oriental Education & Technology Group Earnings Forecast
Key New Oriental Education & Technology Group Financial Ratios
- The Gross Profit Margin over the past 20 years for EDU is 43.51%.
- The Selling, General & Administrative Expenses for EDU have been equal to 75.15% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is -0.34% of Operating Income.
- The Net Earning history of EDU is -38.25% of Total Revenues.
- Per Share Earnings over the last 20 years have been positive in 14 years.
New Oriental Education & Technology Group Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYSE |
|---|---|
| Industry: | Education & Training Services |
| Sector: | Consumer Defensive |
| Current Symbol: | EDU |
| CUSIP: | 647581 |
| Website: | neworiental.org |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 2.4 |
| Quick Ratio: | 2.21 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 20.21 |
EDU Technical Analysis vs Fundamental Analysis
Buy
68
New Oriental Education & Technology Group (EDU)
is a Buy
Is New Oriental Education & Technology Group a Buy or a Sell?
-
New Oriental Education & Technology Group stock is rated a Buy
The current New Oriental Education & Technology Group [EDU] share price is $38.61. The Score for EDU is 68, which is 36% above its historic median score of 50, and infers lower risk than normal.